Publication: Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients".
Loading...
Identifiers
Date
2021-04-03
Authors
Rodriguez-Peralvarez, Manuel
Colmenero, Jordi
Salcedo, Magdalena
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
We read with great interest the letter by G. J. Webb et al. regarding our recent nationwide study promoted by the Spanish Society of Liver Transplantation (SETH), which evaluated the incidence and outcomes of coronavirus disease
2019 (COVID-19) in liver transplant (LT) patients.2 The authors merged the SETH data with their own international cohort (COVID-Hep/SECURE-Cirrhosis)3 resulting in 258 LT patients with COVID-19. The combined data analysis allowed them to highlight the importance of age and comorbidities as key factors influencing outcomes. We completely agree with this conclusion, which may also be true for non-transplant patients with COVID19. However, some statements require further clarification.
Description
MeSH Terms
COVID-19
Calcineurin inhibitors
Comorbidity
Humans
Immunosuppressive agents
Liver transplantation
SARS-CoV-2
Calcineurin inhibitors
Comorbidity
Humans
Immunosuppressive agents
Liver transplantation
SARS-CoV-2
DeCS Terms
Comorbilidad
Inhibidores de la calcineurina
Inmunosupresores
Trasplante de hígado
Inhibidores de la calcineurina
Inmunosupresores
Trasplante de hígado
CIE Terms
Keywords
COVID-19, SARS-CoV-2, Calcineurin inhibitors, Everolimus, Immunosuppression, Mycophenolate, Pneumonia, Tacrolimus, Transplantation
Citation
Rodríguez-Perálvarez M, Colmenero J, Salcedo M; Spanish Society of Liver Transplantation (SETH). Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients". J Hepatol. 2021 Jul;75(1):228-229